Search Results - "Lewis Phillips, G"

515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel by Junttila, T, Fields, C, Li, G, Crocker, L, Parsons, K, Berry, L, Totpal, K, Lewis Phillips, G, Sliwkowski, M

Get full text

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) by Metzger, O., Lambertini, C., Krop, I.E., Lewis Phillips, G., Perou, C.M., Symmans, F., Melero, I., Harbeck, N., Winer, E.P., Im, S-A., Barrios, C.H., Bonnefoi, H., Gralow, J.R., Ellis, P.A., Gianni, L., Toi, M., Swain, S.M., Boulet, T., Song, C., de Haas, S.

Get full text

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC) by de Haas, SL, Hurvitz, SA, Martin, M, Kiermaier, A, Lewis Phillips, G, Xu, J, Helms, H-J, Slamon, D, Press, MF

“…Abstract Introduction KRISTINE (NCT02131064) is an open-label, phase 3 study of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) vs docetaxel +…”
Get full text

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) by Prat, A, Slamon, D, Hurvitz, SA, Press, MF, Lewis Phillips, G, Lopez Valverde, V, Kiermaier, A, Helms, H-J, Martin, M, de Haas, SL

“…Abstract Introduction: Previous studies have shown that HER2+ breast cancer is biologically heterogenous and intrinsic subtypes can be identified (luminal A,…”
Get full text

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 by Junttila, Teemu T., Akita, Robert W., Parsons, Kathryn, Fields, Carter, Lewis Phillips, Gail D., Friedman, Lori S., Sampath, Deepak, Sliwkowski, Mark X.

“…Herceptin (trastuzumab) is the backbone of HER2-directed breast cancer therapy and benefits patients in both the adjuvant and metastatic settings. Here, we…”
Get full text

A novel 96-well scintillation proximity assay for the measurement of apoptosis by MCMURTREY, A. E, GRAVES, R. J, HOOLEY, J, BROPHY, G, PHILLIPS, G. D. L

“…The translocation of phospholipids across the plasma membrane has been widely documented as one of the earliest measurable biochemical events of apoptosis…”
Get full text

237 Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling of xenograft tumor response of Trastuzumab-DM1-antibody drug conjugates by Wada, R, Erickson, H.K, Phillips, G. Lewis, Provenzano, C.A, Leipold, D.D, Pinkas, J, Mai, E, Gupta, M, Johnson, H, Tibbitts, J

Get full text

Abstract S3-6: Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo by Sampath, D, Fields, C, Li, G, Prior, WW, Parsons, K, Friedman, LS, Lewis-Phillips, GD

“…Abstract The receptor tyrosine kinase, HER2/ErbB2, is a validated clinical target for HER2-amplified breast cancer, as evidenced by the U.S.F.D.A. approval of…”
Get full text